Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI-induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib-induced trichomegaly in a Chinese patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509027 | PMC |
| http://dx.doi.org/10.3892/ol.2015.3265 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vorasidenib-Induced Trichomegaly and Hypertrichosis: a New Side Effect in a Patient with Diffuse Astrocytoma.
Dermatol Ther (Heidelb)
October 2024
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 5, 40138, Bologna, BO, Italy.
Article Synopsis
- Vorasidenib is an oral medication that inhibits mutant enzymes to help manage diffuse low-grade gliomas, a type of brain tumor.
- A case study is presented involving a 44-year-old man who developed trichomegaly (long eyelashes) and hypertrichosis (excessive body hair) after one month on the drug.
- This report is significant as it highlights a new side effect linked to vorasidenib, improving awareness of potential adverse reactions in brain tumor treatments.
FGF5.
Differentiation
September 2024
Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, United States. Electronic address:
FGF5 functions as a negative regulator of the hair cycle in mammals. It is expressed in the outer root sheath of hair follicles during the late anagen phase of the hair cycle. It functions as a signaling molecule, mediating the transition of the anagen growth phase to catagen regression phase of the hair cycle.
View Article and Find Full Text PDFPeripheral corneal ulcer secondary to acquired eyelash trichomegaly following treatment with erlotinib in Asia: a case report.
Int J Ophthalmol
March 2023
Department of Ophthalmic Center, Kiang Wu Hospital, Macao 999078, China.
Fibroblast growth factor 5 (FGF5) and its missense mutant FGF5-H174 underlying trichomegaly: a molecular dynamics simulation investigation.
J Biomol Struct Dyn
December 2023
Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey, USA.
The missense mutation Y174H of FGF5 (FGF5-H174) had been associated with trichomegaly, characterized by abnormally long and pigmented eyelashes. The amino acid tyrosine (Tyr/Y) at position 174 is conserved across many species, proposedly holding important characteristics for the functions of FGF5. Microsecond molecular dynamics simulations along with protein-protein docking and residue interacting network analysis were employed to investigate the structural dynamics and binding mode of both wild-type (FGF5-WT) and its mutated counterpart (FGF5-H174).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!